February 9, 2017
Tetraphase antibiotic may reach up to $700 million in annual sales: CEO
Tetraphase Pharmaceuticals Inc Chief Executive Guy Macdonald said annual sales of the company’s lead experimental antibiotic for serious bacterial infections could climb as high as $700 million if approved.